^
    Apply
    Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer (NCT05293964)
    Phase 1
    Jiangsu Simcere Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    05/29/2023
    Initiation :
    05/18/2022
    Primary completion :
    12/31/2024
    Completion :
    09/08/2025
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    Ibrance (palbociclib) • everolimus • SCR-6852